TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03361085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nvHAP Prevention Bundle
Description: oral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable
Study: NCT03324373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial or Radical Cytoreductive Nephrectomy
Description: Surgical removal of a kidney.~After completion of 8 weeks of therapy and restaging, investigators will require 2 weeks wash out period. The patients will be evaluated by urology oncology team and appropriate surgery will be planned. This includes partial nephrectomy and radical nephrectomy.
Study: NCT03025425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trilogy 100 ® (Philips Respironics)
Description: Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
Study: NCT01378559

Intervention type: OTHER
Intervention: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire
Description: A questionnaire accessing satisfaction with a penis prosthesis
Study: NCT03243851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide+Metformin
Description: Low dose temozolomide+metformin for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide+Placebo
Description: Low dose temozolomide+placebo for 24 weeks
Study: NCT01361022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lendormin tablet
Description: Lendormin tablet 250mc is administrated and compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brotizolam tablet
Description: Brotizolam tablet 250mc is administrated and compared
Study: NCT06159452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191-P3 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191-P3 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191-P3 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191-P3 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191-P2 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191-P2 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAR153191-C1F3 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Study: NCT03153774

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of sarcopenia prevalence
Description: Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of sarcopenia prevalence
Description: Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
Study: NCT03217344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: immobilization on sling of the injured arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: immobilization on sling of the injured arm
Study: NCT03037073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 35 patients will receive duloxetine (Cymbalta; Eli Lilly \& Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: 35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
Study: NCT02595983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revusiran
Description: 500mg Revusiran by subcutaneous (sc) injection
Study: NCT00097500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients usual dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients usual dosage
Study: NCT01600885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
Study: NCT00639197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: To tunnel
Description: Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard (not to tunnel)
Description: Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
Study: NCT04616755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.
Description: Measuring changes occurred under 2 years which the retention devices have been in place between the groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.
Description: Measuring changes occurred under 2 years which the retention devices have been in place between the groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.
Description: Measuring changes occurred under 2 years which the retention devices have been in place between the groups
Study: NCT02538744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxazosin
Description: Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 \[placebo\], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 \[placebo\], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cocaine
Description: On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cocaine
Description: On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05963334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin/paclitaxel
Description: Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel
Description: Weekly dose versus every three weeks dense dose of carboplatin/paclitaxel regimen in advanced epithelial ovarian cancer.
Study: NCT01895075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Description: Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2 ml normal saline by inhalation
Study: NCT03120884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI
Description: A technique that involves microinjection of spermatozoa into mature oocytes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF
Description: A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
Study: NCT03912012

Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol renal clearance measurement
Description: intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.

Intervention type: DEVICE
Group type: OTHER
Intervention: microcirculation assessment through Laser Doppler associated to iontophoresis.
Description: endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement
Description: carotid ultrasound (during Day 1)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: 37 mL of blood sample will be performed at Day 1

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Urine sampling
Description: The urinary collection will be done during the Day 1, on the first morning urination

Intervention type: DEVICE
Group type: OTHER
Intervention: High-resolution peripheral quantitative computed tomography (HR-pQCT)
Description: assessment of the Body Mass Index by HR-pQCT (during the Day 1)

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual-energy X-ray (DXA)
Description: assessment of bone parameters by DXA (during the Day 1)
Study: NCT01546103

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 1000 IU by mouth, once daily for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 5000 IU by mouth, once daily for 3 months.
Study: NCT00517764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
Study: NCT02616510

Intervention type: PROCEDURE
Intervention: cardiovascular screening
Description: cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound

Intervention type: PROCEDURE
Intervention: cardiovascular screening
Description: cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
Study: NCT02385929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing therapy & resistance training
Description: i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.~iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards.
Study: NCT02490683

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Luna Rich X

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reliv Now
Study: NCT03081702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole is approved and used for the treatment of certain systemic fungal infections.
Study: NCT02724332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: 2mg,po,bid
Study: NCT01299844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Peer Counseling
Description: 16 Home visits from a bilingual/bicultural diabetes peer counselor.
Study: NCT02738814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: When severe emergence agitation(PAED \> 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
Study: NCT02694744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: 8.4 g/day starting dose, administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patiromer
Description: 8.4 g/day starting dose, administered orally
Study: NCT03442816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHRC Camera
Description: Evaluate the technical capabilities of the device to obtain quality images in reflectance and fluorescence imaging modes in a diverse population.
Study: NCT00686777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alfa-2b
Description: Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 400 mg/day orally
Study: NCT04942587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LISTENING TO THE RECORDINGS SAYING BY PARENTS
Description: The baby was made listen to the lullaby recorded in the voice of parents starting with, during and after the care for 10 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LISTENING TO THE RECORDINGS SAYING BY PARENTS
Description: The baby was made listen to the lullaby recorded in the voice of parents starting with, during and after the care for 10 minutes.
Study: NCT04383509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
Study: NCT00792844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-K capsule formulation
Description: Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bio-K drink
Description: Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
Study: NCT02571426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: anesthetic agent
Study: NCT01663870

Intervention type: BEHAVIORAL
Intervention: Audio Recorded Interviews
Description: Audio recorded interview at beginning of visit and after using HealthATM website.

Intervention type: BEHAVIORAL
Intervention: Audio Recorded Interviews
Description: Audio recorded interview at beginning of visit and after using HealthATM website.

Intervention type: BEHAVIORAL
Intervention: Focus Group Session
Description: Focus group session taking 60-90 minutes.

Intervention type: OTHER
Intervention: Website Session
Description: 10-15 minute session with the HealthATM website.

Intervention type: OTHER
Intervention: Website Session
Description: 10-15 minute session with the HealthATM website.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion at end of audio recorded interview taking about 5 minutes.